We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is CytomX Therapeutics (CTMX) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is CytomX Therapeutics (CTMX - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
CytomX Therapeutics is a member of our Medical group, which includes 887 different companies and currently sits at #1 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. CTMX is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for CTMX's full-year earnings has moved 80.19% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, CTMX has returned 0.48% so far this year. In comparison, Medical companies have returned an average of -1.42%. This shows that CytomX Therapeutics is outperforming its peers so far this year.
Looking more specifically, CTMX belongs to the Medical - Biomedical and Genetics industry, which includes 381 individual stocks and currently sits at #44 in the Zacks Industry Rank. On average, this group has gained an average of 9.11% so far this year, meaning that CTMX is slightly underperforming its industry in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to CTMX as it looks to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is CytomX Therapeutics (CTMX) Stock Outpacing Its Medical Peers This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is CytomX Therapeutics (CTMX - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
CytomX Therapeutics is a member of our Medical group, which includes 887 different companies and currently sits at #1 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. CTMX is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for CTMX's full-year earnings has moved 80.19% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, CTMX has returned 0.48% so far this year. In comparison, Medical companies have returned an average of -1.42%. This shows that CytomX Therapeutics is outperforming its peers so far this year.
Looking more specifically, CTMX belongs to the Medical - Biomedical and Genetics industry, which includes 381 individual stocks and currently sits at #44 in the Zacks Industry Rank. On average, this group has gained an average of 9.11% so far this year, meaning that CTMX is slightly underperforming its industry in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to CTMX as it looks to continue its solid performance.